{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:59:59Z","timestamp":1781175599097,"version":"3.54.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Here, we report a case of a 52-year-old woman with a well-differentiated, metastasized neuroendocrine tumor (NET G1) of the duodenum. Initial imaging with <jats:sup>68<\/jats:sup>Ga-DOTATOC revealed multiple sites of disease with intense uptake. Peptide receptor radionuclide therapy (PRRT) with <jats:sup>177<\/jats:sup>Lu-DOTATOC induced partial remission. Treatment was then switched to cold somatostatin analog as a maintenance therapy. After 2 years of follow-up, progressive disease with multiple lesions in the skeleton was noted. Given the initial response to PRRT, a rechallenge with another 2 cycles of PRRT were given, and the patient had an excellent response to treatment, in particular in the skeleton.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004239","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T18:02:47Z","timestamp":1650391367000},"page":"719-720","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Rechallenge With Additional Doses of 177Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs"],"prefix":"10.1097","volume":"47","author":[{"given":"Alexander","family":"Weich","sequence":"first","affiliation":[{"name":"Internal Medicine II, Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-017-0461-5","article-title":"Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract","volume":"18","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00259-013-2547-z","article-title":"Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.7150\/thno.30357","article-title":"The theranostic promise for neuroendocrine tumors in the late 2010s\u2014where do we stand, where do we go?","volume":"8","year":"2018","journal-title":"Theranostics"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","article-title":"Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2967\/jnumed.114.143974","article-title":"PRRT: defining the paradigm shift to achieve standardization and individualization","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/curroncol28010015","article-title":"Efficacy of 177Lu-Dotatate induction and maintenance therapy of various types of neuroendocrine tumors: a phase II registry study","volume":"28","year":"2020","journal-title":"Curr Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2967\/jnumed.120.253450","article-title":"Mars shot for nuclear medicine, molecular imaging, and molecularly targeted radiopharmaceutical therapy","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.118.220665","article-title":"Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine","volume":"61","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:01:41Z","timestamp":1750536101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004239","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}